The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis.
The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).
T2DM risk reduced by 39 percent for those with high adherence to antimalarial therapy for managing lupus.
Lower income associated with higher incidence of lupus nephritis, ANCA-related glomerulonephritis.
A study found that renal arteriosclerosis develops 2 decades earlier in patients with lupus nephritis compared with healthy age-matched controls.
GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.
The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis.
Voclosporin was found to be superior to standard-of-care treatment in patients with lupus nephritis, according to data from the phase 3 AURORA trial.
This study reports the long-term renal outcomes of kidney biopsies performed at prespecified intervals to determine the safety and accuracy of tapering of maintenance immunosuppression.